[{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"\nFe||","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rockwell Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rockwell Medical \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-C3","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-C3","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-C3","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ValenzaBio","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Series A Financing","leadProduct":"CD19-targeting mAb","moa":"CD19","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"ValenzaBio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"ValenzaBio \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"7","companyTruncated":"ValenzaBio \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kyverna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kyverna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kyverna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kyverna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Kyverna Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VB119","moa":"CD19","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eliem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eliem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MIL62","moa":"CD20","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Mabworks Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Mabworks Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Eleva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Factor H","moa":"CFH","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Eleva","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eleva \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eleva \/ Undisclosed"},{"orgOrder":0,"company":"AbelZeta Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"C-CAR168","moa":"Claudin 18.2","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"AbelZeta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbelZeta Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbelZeta Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PT. JES Kasih Nusantara Sejahterah","sponsor":"RSPAD Gatot Soebroto | Universitas Prima Indonesia | Universitas Pertahanan Indonesia","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDONESIA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Dendritic Cell Immunotherapy","moa":"Dendritic cell","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"PT. JES Kasih Nusantara Sejahterah","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PT. JES Kasih Nusantara Sejahterah \/ RSPAD Gatot Soebroto | Universitas Prima Indonesia | Universitas Pertahanan Indonesia","highestDevelopmentStatusID":"7","companyTruncated":"PT. JES Kasih Nusantara Sejahterah \/ RSPAD Gatot Soebroto | Universitas Prima Indonesia | Universitas Pertahanan Indonesia"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Ossium Health | ITBMed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Ossium Health | ITBMed","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Ossium Health | ITBMed"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Henlius","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Licensing Agreement","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Henlius","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Henlius"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Disc medicine \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Immune","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Carbohydrate","year":"2025","type":"Public Offering","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Immune||Toll-like-4 receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Immune||Toll-like-4 receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Immune||Toll-like-4 receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Revelation Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revelation Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Felzartamab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HI-Bio \/ Undisclosed"},{"orgOrder":0,"company":"Grand Life Science","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lanthanum Polystyrene Sulfonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Grand Life Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Grand Life Science \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"7","companyTruncated":"Grand Life Science \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"Samuel Vilchez, PhD","sponsor":"Ministerio de Salud de Nicaragua | GID BIO | National Autonomous University of Nicaragua","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Adipose-Derived Stromal Vascular Fraction Cell","moa":"Progenitor cell","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Samuel Vilchez, PhD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samuel Vilchez, PhD \/ Ministerio de Salud de Nicaragua | GID BIO | National Autonomous University of Nicaragua","highestDevelopmentStatusID":"7","companyTruncated":"Samuel Vilchez, PhD \/ Ministerio de Salud de Nicaragua | GID BIO | National Autonomous University of Nicaragua"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Povetacicept","moa":"TNFRSF13B","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Immunophage Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IPG11406","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Nanjing Immunophage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Immunophage Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanjing Immunophage Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SCTC21C","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Vascudyne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Arteriovenous Conduit","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Vascudyne","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascudyne \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vascudyne \/ Undisclosed"},{"orgOrder":0,"company":"AION Healthspan, Inc.","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AION-301","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"AION Healthspan, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AION Healthspan, Inc. \/ George Clinical","highestDevelopmentStatusID":"7","companyTruncated":"AION Healthspan, Inc. \/ George Clinical"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"University of Texas Health Science Center at Houston | University of California, San Francisco | University of Alabama at Birmingham","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Human Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Biosciences \/ University of Texas Health Science Center at Houston | University of California, San Francisco | University of Alabama at Birmingham","highestDevelopmentStatusID":"7","companyTruncated":"Hope Biosciences \/ University of Texas Health Science Center at Houston | University of California, San Francisco | University of Alabama at Birmingham"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aro-Cfb","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ARO-CFB","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"ARO-CFB","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Abu Dhabi Health Services Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.A.E","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Gum Arabic","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Abu Dhabi Health Services Company","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Abu Dhabi Health Services Company \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Abu Dhabi Health Services Company \/ Undisclosed"},{"orgOrder":0,"company":"Kelifarma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KELI-101","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Kelifarma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kelifarma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kelifarma \/ Undisclosed"},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Orbsen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orbsen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Orbsen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"NB1000S","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novome Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Tencent","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Series B Financing","leadProduct":"NB1000S","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Novome Biotechnologies \/ Tencent","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Tencent"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Zhongyuan Xiehe Biological Cell Storage Service (Tianjin) Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tongji Hospital \/ Zhongyuan Xiehe Biological Cell Storage Service (Tianjin) Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Tongji Hospital \/ Zhongyuan Xiehe Biological Cell Storage Service (Tianjin) Co., Ltd."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vonsetamig","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Xenokidney","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"United Therapeutics \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : MIL62 is a drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Lupus Nephritis.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 29, 2025

                          Lead Product(s) : MIL62

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : The Company intends to use the net proceeds for the development of its product candidates, including Gemini aka phosphorylated hexaacylated disaccharide Phase 1b clinical study.

                          Product Name : Gemini

                          Product Type : Carbohydrate

                          Upfront Cash : Undisclosed

                          May 29, 2025

                          Lead Product(s) : Phosphorylated Hexaacyl Disaccharide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Roth Capital Partners

                          Deal Size : $4.0 million

                          Deal Type : Public Offering

                          blank

                          03

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : C-CAR168 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lupus Nephritis.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 20, 2025

                          Lead Product(s) : C-CAR168

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Palleon and Henlius to evaluate Palleon’s E-602 (HLX79) in combination with Henlius’ HANLIKANG (rituximab) in clinical trials for autoimmune diseases including lupus nephritis.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          April 02, 2025

                          Lead Product(s) : Bi-Sialidase,Rituximab

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Shanghai Henlius Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Xenokidney is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Kidney Failure, Chronic.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 17, 2025

                          Lead Product(s) : Xenokidney

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : ARO-C3 is a RNAi therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          March 10, 2025

                          Lead Product(s) : ARO-C3

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PT. JES Kasih Nusantara Sejahterah

                          Country arrow
                          BioJapan
                          Not Confirmed

                          PT. JES Kasih Nusantara Sejahterah

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Lead Product(s) : Dendritic Cell Immunotherapy

                          Therapeutic Area : Nephrology

                          Study Phase : Phase I/ Phase II

                          Sponsor : RSPAD Gatot Soebroto | Universitas Prima Indonesia | Universitas Pertahanan Indonesia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Nusantara (Dendritic Cell Immunotherapy) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetic Nephropathies.

                          Product Name : Nusantara

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          March 10, 2025

                          Lead Product(s) : Dendritic Cell Immunotherapy

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : RSPAD Gatot Soebroto | Universitas Prima Indonesia | Universitas Pertahanan Indonesia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Gemini (Phosphorylated Hexaacylated Disaccharide) is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Renal Insufficiency, Chronic.

                          Product Name : Gemini

                          Product Type : Carbohydrate

                          Upfront Cash : Inapplicable

                          March 07, 2025

                          Lead Product(s) : Phosphorylated Hexaacylated Disaccharide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Abu Dhabi Health Services Company

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Abu Dhabi Health Services Company

                          Country arrow
                          BioJapan
                          Not Confirmed

                          Details : Gum Arabic is a Dietary Supplement drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Kidney Failure, Chronic.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          February 20, 2025

                          Lead Product(s) : Gum Arabic

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : SCTC21C is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glomerulonephritis, IGA.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 14, 2025

                          Lead Product(s) : SCTC21C

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank